Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2016-03-17 Earnings Release
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
THR FY15 Press Release EN FINAL_17032016.pdf
Earnings Release Classification · 95% confidence The document is explicitly titled as a 'Press release' dated March 17, 2016, and states it 'today issues a business update and its financial update for the year ending December 31, 2015.' It provides highlights, strategy updates, R&D pipeline details, and financial figures for the preceding year (2015). This structure—a summary announcement of annual performance and future outlook released around the time of the annual report filing—is characteristic of an Earnings Release (ER) or a comprehensive business update that often precedes or accompanies the full 10-K. Since it contains detailed financial highlights (€11.2 million revenue, cash position) and extensive operational updates, it goes beyond a simple 'key highlights only' ER, but it is not the full, audited 10-K document itself. However, given the comprehensive nature of the financial and operational review for the full year, and the fact that it is a press release summarizing the year's performance, it most closely aligns with an Earnings Release (ER) or a Management Discussion & Analysis (MDA) summary. Since it is a press release format summarizing the full year's results and outlook, ER is the most appropriate fit among the choices, as it serves as the initial public announcement of the annual performance summary. FY 2015
2016-03-17 English
THR FY15 PR EN 040316-final dutch_17032016.pdf
Management Reports Classification · 99% confidence The document is a press release dated March 17, 2016, announcing the business and financial update for the year ending December 31, 2015. It contains highlights, strategic updates, R&D pipeline details (focusing on diabetic eye disease), updates on the spin-off Oncurious, commercial updates for JETREA®, management appointments, and detailed financial figures for the year 2015. The content is comprehensive, covering strategy, operations, and full-year financials, which strongly suggests an Annual Report or a detailed report summarizing the year. However, since it is explicitly titled as a 'Persbericht' (Press Release) announcing the update for the year ending December 31, 2015, and includes management commentary and detailed pipeline information typical of a full-year review, it aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Interim/Annual Report (IR/AR). Given the full-year scope and detailed financial review (€101.4 million cash at year-end, €11.2 million total revenue for 2015), it is a comprehensive annual disclosure. Since the definition for 10-K is 'Official yearly report covering company activity and full financial performance,' and this document serves that function via a press release format summarizing the year, 10-K is the most appropriate classification for the underlying information type, even if the format is a press release. If a specific 10-K filing document was not present, this serves as the primary annual disclosure. The presence of management appointments and detailed financial review supports this. It is not merely an Earnings Release (ER) as it covers the entire year and strategy in depth, nor is it just an Audit Report (AR) as it contains operational and strategic updates.
2016-03-17 Dutch
PR_THR Clay Transparency 140116_EN.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "*Regulated Information - Transparency Statement*" and details notifications received regarding changes in shareholdings by specific individuals (Mr. Thomas M. Clay and Mr. Landon T. Clay) and controlled entities, referencing Belgian transparency legislation. It explicitly lists current major shareholdings. This content directly relates to insider transactions and significant ownership changes, which falls under the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the core content is the notification of personal share transactions by directors/executives crossing thresholds, Director's Dealing (DIRS) is the most specific fit, although Major Shareholding Notification (MRQ) is also relevant. Given the focus on specific individuals' holdings changing relative to thresholds, DIRS is chosen as the primary classification for insider transaction reporting, which often triggers these transparency statements. The document is a direct announcement, not a summary or a report itself, making RPA/RNS less appropriate than the specific content category.
2016-01-15 English
PR_THR Clay Transparency 140116_NL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Gereglementeerde informatie - Transparantieverklaring" (Regulated information - Transparency declaration) and details the shareholdings of specific individuals (Dhr. Thomas M. Clay and Dhr. Landon T. Clay) in ThromboGenics NV, referencing Belgian transparency legislation. This type of filing specifically reports changes or current status of significant share ownership by insiders or major shareholders, crossing ownership thresholds. This aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is a regulatory announcement, MRQ is a more specific category than the general RNS fallback.
2016-01-15 Dutch
PR_THR Clay Transparency 081215 EN_FINAL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "Regulated Information - Transparency Statement" and details notifications received regarding changes in significant shareholdings by specific individuals (Mr Landon T. Clay and Thomas M Clay) and lists the current major participations. This directly corresponds to the definition of a Major Shareholding Notification, which reports changes in significant ownership levels crossing thresholds. The appropriate code is MRQ.
2015-12-08 English
PR_THR Clay Transparency 081215 NL_FINAL.pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal announcement, indicated by the header "*Gereglementeerde informatie* - *Transparantieverklaring*" (Regulated information - Transparency declaration). The core content details changes in shareholdings by specific individuals (Mr Landon T. Clay and Mr Thomas M. Clay) and lists the resulting major shareholdings as of a specific date (November 23, 2015). This type of filing, reporting changes in significant ownership stakes that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). It is not an Earnings Release (ER), a full Annual Report (10-K), or a Director's Dealing report (DIRS), as it reports on major shareholders rather than just director transactions or general earnings. It is a specific regulatory disclosure regarding ownership structure.
2015-12-08 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.